A Phase 4 interventional study of Olanzapine and Aripiprazole in Schizophrenia, sponsored by Eli Lilly and Company. Completed at 24 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2007-07-18.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.
Among the 97 studies testing olanzapine in Schizophrenia, this one is the 14th largest by enrollment of the 94 interventional ones that give a count, is one of 10 that started in 2003, is one of 46 in phase 4, and was the 11th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
By country, each count listing its studies:
Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8 · Phase 3 25 · Phase 4 46
First in 1997; this study’s year is marked. 10 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 560 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 114 across the 94 interventional studies. Of the 86 that completed or were terminated, 25 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 97 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
33 studies in Schizophrenia by Eli Lilly and Company: 2 open now, 2 under way, none of them phase 3. Of 31 finished, 9 (29%) have results posted.
Among the 33 studies in Schizophrenia by Eli Lilly and Company, this one is the 6th largest by enrollment of the 29 interventional ones that give a count, is one of 6 that started in 2003, is one of 16 in phase 4, and was the 5th registered.
Eli Lilly and Company’s Schizophrenia studies by the year they started, since 2001.
2 of the studies testing olanzapine in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03781115University of ArizonaProposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia | 2027-02-10 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 97 studies testing olanzapine in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 33 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the protocol is to evaluate the efficacy of olanzapine compared with Aripiprazole in patients with schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
To determine the long-term effectiveness and tolerability as measured by time to all-cause treatment discontinuation of olanzapine and aripiprazole relative to each other in patients with schizophrenia during 28 weeks of double-blind therapy
To assess olanzapine versus aripiprazole in the following:
improvement in psychopathology of schizophrenia as measured by PANSS change
change in CGI-S and PGI-I scores
level of activation as measured by PANSS change
depressive symptoms as measured by MADRS score
response rates
time to failure to maintain response
quality of life as measured by the SWN-S and SF-36
cognitive functioning as measured by the MOS
sexual functioning as measured by the GISF
health resource utilization and resource utilization costs
hospitalization time
treatment emergent adverse events
EPS as measured by the Simpson-Angus, Barnes, and AIMS
laboratory values
vital signs
The record gives a start of Oct 2003 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Olanzapine · Aripiprazole